British Columbia Cancer Agency the Vancouver Centre

Vancouver, British Columbia V5Z 4E6

3 studies enrolling now · 5 studies all time

What they study most

B-cell Malignancy, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Non-Hodgkin Lymphoma, Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Multiple Myeloma, Small Lymphocytic Lymphoma

Studies at this site

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — Recruiting now
• A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma — Recruiting now
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — Recruiting now
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma — Running, not enrolling